Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7MW3711 and JS207 in Advanced Solid Tumors
NCT07466160Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of 7MW3711 in solid tumor, sponsored by Mabwell. Primary endpoints: Incidence and severity of adverse events at 2 years, Maximum tolerated dose at 2 years and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
7MW3711
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07466160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466160.